Edwards Lifesciences (NYSE:EW) Stock: Insider Daniel Lippis Sells 619 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $85.65, for a total transaction of $53,017.35. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at $3,428,912.10. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Trading Up 1.2%

NYSE EW opened at $85.27 on Friday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market cap of $49.10 billion, a PE ratio of 49.00, a price-to-earnings-growth ratio of 2.21 and a beta of 0.87. The company has a 50 day moving average price of $88.72 and a 200 day moving average price of $86.16. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same period last year, the firm earned $0.67 earnings per share. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3.00 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on EW shares. Evercore reaffirmed an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, September 26th. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Edwards Lifesciences in a research report on Friday, September 11th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently modified their holdings of EW. BlackRock Inc. acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $5,318,092,000. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $1,274,082,000. Bank of America Corp DE acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $605,397,000. Deutsche Bank AG purchased a new stake in Edwards Lifesciences during the second quarter worth $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Edwards Lifesciences by 0.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock worth $496,503,000 after buying an additional 30,495 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.